cisplatin + pemetrexed + sunitinib

This is a combination regimen consisting of three drugs: - **Cisplatin** is a platinum-based chemotherapy agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. - **Pemetrexed** is an antifolate antineoplastic agent that inhibits multiple folate-dependent enzymes involved in the synthesis of thymidine and purine nucleotides, thereby disrupting DNA and RNA synthesis essential for cell replication[4][5]. - **Sunitinib** is an oral small molecule multi-targeted tyrosine kinase inhibitor (TKI) that blocks several receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), KIT, FLT3, RET, and CSF1R. This inhibition disrupts tumor angiogenesis and cell proliferation[6][8][10]. This specific triple combination does not have a unique brand or code name; it represents the concurrent use of these three agents. While cisplatin plus pemetrexed is approved for non-squamous non-small cell lung cancer (NSCLC) and mesothelioma[1][5], sunitinib is approved as monotherapy for renal cell carcinoma, gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors[6][8][10]. The triple combination may be explored in clinical trials or investigational settings but does not represent an established standard-of-care regimen.